Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysisThe risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han populationPharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications.Ticagrelor: a review of its use in adults with acute coronary syndromes.Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study."East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome.Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
P2860
Q26775125-9A8ADD5D-7853-43C2-8BEE-7E073595DE74Q26801867-CDA3550B-F2D2-4562-B4F8-3A63A9A32CA5Q26998331-2182B544-9987-46ED-AE38-45AE81BD672DQ27006031-D7033594-F628-4A6E-9AA0-C11798F1F05CQ34441355-1567F9C8-D957-456C-9C77-337E0DBD5137Q36328226-D0DD4591-5724-4BFC-B2B4-75DA2929B3ACQ38151563-39754264-8B47-42BA-B72A-2E4D450CF9FAQ38177048-EAD31E5D-BEA7-44F7-BEED-73C39211A14AQ38194963-2053CACD-E696-4531-85FC-FB509D0D6BCAQ38352069-D48F291D-53DF-4002-8018-CFDAB58B29C7Q38381383-CB8DD57E-9D47-4E3D-9CB1-9F7D13AEF4FDQ38750444-E9C4E582-7DE7-44B5-9C76-326B40A1597DQ38958862-A55B2987-51C8-46A7-8ED0-32AB2F41CD9EQ41060485-5EDC9711-B475-4D07-9D19-4ECF20AF1017Q41343370-E7D920F1-F90E-4093-8A8E-10A96B037543Q41511099-8E880B98-F8EF-4511-B4E5-12376A29EEEEQ42375730-E5559AF6-67E4-428B-AC14-4F152DABA92AQ45260812-ED38DE62-A034-4579-938A-9DF7B68CE2C3Q47731076-0158350A-CE8C-4E0E-AC5D-C1977F040E4D
P2860
Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetic, pharmacodynam ...... antiplatelet agent ticagrelor.
@en
type
label
Pharmacokinetic, pharmacodynam ...... antiplatelet agent ticagrelor.
@en
prefLabel
Pharmacokinetic, pharmacodynam ...... antiplatelet agent ticagrelor.
@en
P2860
P1476
Pharmacokinetic, pharmacodynam ...... antiplatelet agent ticagrelor.
@en
P2093
Renli Teng
P2860
P304
P356
10.2165/11630960-000000000-00000
P577
2012-05-01T00:00:00Z
P6179
1001469730